| A | | | B | | | C | | | D | | | E | | | F | | | G | | | H | | | I | | | J | | | K | | | L | | | M | | | N | | | O | | | P | | | Q | | | R | | | S | | | T | | | U | | | V | | | W | | | X | | | Y | | | Z |
Dr. Jonas AndersHead of Marketing Chromatography, EMD Millipore Dr. Jonas Anders has more than 15 years of experience in various R&D, marketing and management functions in the area of Life Sciences. He graduated as a chemical engineer at the Technical University in Darmstadt, Germany 1994 and has received his Ph.D. from the University of Mainz in 1998. After that, he worked in various R&D functions at the Karolinska Institute in Stockholm, Sweden and at Merck, KGaA, Darmstadt, Germany, where he joined in 2001. After managing different strategic projects, Jonas took over the business responsibility for Merck´s downstream processing business and is now responsible for Merck Millipore´s global bioprocess purification chromatography business.
|
Michael BavandChief Business Officer and Board Chairman, Michael Bavand, Ph.D., joined ChromaCon in 2009 as an investor and board chairman and has also assumed operational responsibility as a CBO. An entrepreneur helping to found and develop several profitable businesses, Michael has more than 20 years of business, R&D and operational experience gained in the biopharmaceutical industry with assignments at Roche (former Boehringer Mannheim), Serono, Selexis, Siegfried, RCC, and Kuros. A chemist and biologist by training, Michael has also studied International Marketing and has obtained executive education from Stanford Business School (SEP) and Harvard Business School (Operations Strategy). Michael is responsible for Marketing and Sales, BD and Licensing.
|
Gregory S. Blank, Ph.D.Bioprocess Consultant, USA Dr. Blank is a recognized global leader in Bioprocess development. He spent over 23 years at Genentech most recently as Director of the Late Stage Purification Department responsible for development of commercial processes, post approval changes, and process validation. Also reporting to Dr. Blank was the virus validation group. He received his Ph.D. in cell biology from the University of Southern California in 1981. Following post-doctoral fellowships at Case Western University School of Medicine and Becton Dickinson Monoclonal Center he joined the Recovery Sciences Department at Genentech in 1987.He became department director in 2000. TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers. While at Genentech he has focused on monoclonal antibody process technology and has led the development and commercial scale-up of recovery processes for both full-length antibodies (including Rituxan, Herceptin, and Raptiva) from mammalian cells and antibody fragments from bacteria. The purification processes Dr. Blank developed for Herceptin and Rituxan have formed the purification platform for all of Genentech’s monoclonal antibodies. He has also helped develop Genentech’s approach to process validation including virus validation, modular validation, and Quality by Design. He has over 40 publications and patents in areas of process development, process validation, manufacturing operations, virus validation, documentation and has lectured extensively in these areas. He currently has an appointment as an Adjunct Professor in the Department of Pharmaceutical Chemistry, University of Kansas and is also on the Scientific Advisory Board of the IBC Life Science Division and the Editorial Board of BioProcessing Journal.
|
Tim BreeceSenior Scientist Tim Breece is currently a Senior Scientist in Purification Development at Xoma in Berkeley, California, a position he has held since 2009. Prior to this, he was at Genentech for 24 years with positions in the Technology Assessment, Purification Development and Manufacturing departments. He has submitted four patents, several journal articles and many oral presentations. From 2002-2010, he served as an instructor for the American Society of Mechanical Engineers Bioprocessing Technical Seminars lecturing on chromatography scale-up and monoclonal antibody purification. He received his BS in chemical engineering and applied biology from the University of California at Berkeley.
|
Prof. Dr. Christian FrechHead of the Institute for Biochemistry Prof. Dr. Christian Frech is currently Head of the Institute for Biochemistry at the Mannheim University of Applied Sciences in Germany, a role he has held since 2004. He has also served as the Director of the Steinbeis Transfer Center since 2004. In 2002, Prof. Dr. Christian Frech was appointed Professor for Bioanalytics at the Mannheim University of Applied Sciences. From 1996-2002, he was the Head of Pilot Plant Protein Purification in the Process Development department at Chiron Behring (now Novartis vaccines) in Marburg, Germany. He completed his postdoctoral work at Boehringer Mannheim (now Roche Diagnostics) in Penzberg, Germany.
|
Prof. Dr. Thomas HergetHead of Processing Technologies Prof. Dr. Thomas Herget is currently Head of Processing Technologies within the Merck Millipore process solutions division of Merck KGaA, where he develops new methods and materials for bioprocessing. He is also a medical professor at the University of Mainz and a biochemistry professor at the TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers. From 2004-2010, Prof. Dr. Thomas Herget served as the Director, New Technology Evaluation within Merck KGaA’s Chemicals R&D division. In that role, he ran laboratories in Darmstadt (Germany) and oversaw the R&D activities of Novagen (Madison) and Calbiochem (San Diego). In 2000, he joined the Munich-based Axxima Pharmaceuticals AG (now GPC Biotech), a biotech startup founded by Prof. Axel Ullrich, to focus on the development of protein kinase inhibitors in infectious diseases. He became the company’s Director of Therapeutic Indications. In 1998, he was awarded the Boehringer Ingelheim Research Prize and was appointed professor at the University of Mainz in Germany. As a postdoctoral fellow, he had started an independent research group at the university, elucidating signal transduction mechanisms leading to neural differentiation and apoptosis. Also during his postdoctoral work, he studied cell cycle control mechanisms at the Imperial Cancer Research Fund in London, UK. He studied biology and received his PhD working on gene expression profiling during muscle development in Cologne, Germany.
|
Paul JorjorianManager Purification Development, Gallus Biopharmaceutical Paul Jorjorian joined Gallus Biopharmaceuticals in late 2011 as the lead of the purification development group. His team specializes in the development, tech transfer and scale-up of purification processes for use in cGMP manufacturing. Prior to joining Gallus Paul worked as an Engineer for Bristol Myers Squibb, Syracuse, NY managing multiple development projects for early and late stage products. Paul holds a B.S. in Chemical Engineering with a minor in Management from Purdue University, West Lafayette, IN and a Masters in Chemical Engineering from Cornel University, Ithaca, NY.
|
|
|
Prof. Dr. Massimo MorbidelliProfessor for Chemical- and Bioengineering, Massimo Morbidelli, Prof. ETH, PhD, received his PhD in Chemical Engineering at the University of Notre Dame (USA) in 1986. After his first appointments as professor at the University of Cagliari (Italy) and Politecnico di Milano, he is since 1997 Professor at the Institute for Chemical and Bioengineering at ETH Zurich. Massimo Morbidelli is co-author of more than 500 papers, 11 international patents and four books. He serves as a member of the Editorial Board of several international scientific journals, is associate editor of Industrial & Engineering Chemistry Research (ACS) and is a member of the Scientific Advisory Board of the Max-Planck Institute for Dynamics and Complex Technical Systems, Magdeburg, Germany. He is the recipient of the 2005 R.H. Wilhelm Award in Chemical Reaction Engineering of the American Institute of Chemical Engineers. In the area of preparative chromatography, Massimo Morbidelli did pioneering work for the spreading of SMB-technology as purification process in the pharmaceutical industry. His research group in preparative chromatography belongs to the leading groups in the world. Since 2007, Massimo Morbidelli is chairman of ChromaCon Ltd., a spin-off company from his research group. ChromaCon Ltd. brings new chromatographic processes (MCSGP-technology) for the purification of proteins and peptides to the market.
|
Franz NothelferAssociate Director Protein Science He started his education as biology assistant in 1971 at Dr. Karl Thomae GmbH, a 100% subsidiary of Boehringer Ingelheim Pharma GmbH. In 1979 he joined the newly founded biotechnology group and he started his career in protein chemistry and purification development for recombinant proteins and antibodies. Since 2003 he has served as associate director purification and formulation development at Boehringer Ingelheim Pharma GmbH & Co. KG.
|
Michael Phillips Ph.DResearch Fellow, EMD Millipore, USA Michael received his Ph.D. in chemical engineering from Rensselaer with a primary focus on preparative-scale chromatographic purification of biomolecules. He has over twenty years experience with EMD Millipore and currently leads a team that is investigating and developing new separation technologies for the downstream purification of biotherapeutics. Michael has authored multiple publications, book chapters, conference presentations, and patents in both bead-based and membrane-based chromatographic separations.
|
Michael Schulte, Ph.DSenior Director within the Performance Materials division of Merck KGaA, Darmstadt, Germany Dr. Michael Schulte is currently a Senior Director within the Performance Materials division of Merck KGaA, a role he has held since January 2011. He has worked in various R&D positions at Merck KGaA since 1995, and has published more than 20 scientific articles and more than 50 conference contributions. He received his PhD working on the synthesis and chromatographic use of chiral polymers at the University of Münster in Germany.
|
Prof. Dr. Hartmut SchlüterHead of Core Facility Mass Spectrometric Proteomics Prof. Dr. Hartmut Schlüter is currently Head of Core Facility Mass Spectrometric Proteomics at the Institute of Clinical Chemistry at the University Medical Center Hamburg-Eppendorf (UKE) in Germany. He holds three patents and has published widely on the subject of chromatography, and also serves as the guest editor for Amino Acids and as a reviewer for a variety of scientific journals and funding agencies. From 2000-2008, Prof. Dr. Schlüter served as the Head of the Bioanalytical Laboratory, Nephrology, at the Charite, University Medicine Berlin. Prior to that role, he was a Group Leader of the Medical Faculty of the Ruhr-University of Bochum in Germany. From 1991-1996, he completed his postdoctoral fellowship in nephrology at the University of Münster. He received his doctorate from the University of Münster’s Institute of Biochemistry in 1991.
|
Dr. Romas SkudasLab Leader of Process Purification Downstream Technologies, Merck Millipore, Germany Dr. Romas Skudas is currently a lab leader within Merck Millipore’s Process Purification Downstream Technologies group, a position he has held since 2011. He has worked at Merck Millipore since 2004 on a variety of topics, including the synthesis and characterization of silica particles and the characterization and modeling of optimal silica monolith structures. Dr. Skudas has authored several journal articles and book chapters, and he has presented at a range of industry conferences. He holds a doctorate degree in analytical and inorganic chemistry from Johannes Gutenberg University in Germany.
|
Guido StröhleinCEO and Board Member, ChromaCon, Germany Guido Ströhlein, MBA MTEC ETH, Dr. sc. ETH, Dipl.-Ing., is a co-founder of ChromaCon AG and serves since its incorporation as CEO. He earned his PhD under the guidance of Prof. Morbidelli in the area of preparative chromatography of proteins and small molecules at the ETH Zürich. In parallel to his PhD, Guido received a MBA in Management, Technology and Economics from the ETH Zürich. Previously, he obtained his master in chemical engineering from the Technical University Hamburg-Harburg, Germany with stays at the University of Bradford (GB), DOW Chemical, MI, USA in R&D and a diploma thesis in preparative chromatography at Bayer AG, Leverkusen, Germany.
|
Prof. Klaus K. UngerInstitute for Inorganic Chemistry and Analytical Chemistry Johannes Gutenberg-University, Mainz, Germany Prof. Klaus K. Unger studied chemistry at the Technical University of Darmstadt/TUD), Germany, and completed his PhD in 1965 at the Zintl-Institute of Physical Chemistry and Inorganic Chemitry with Prof. H. W. Kohlschuetter. In 1969 he completed his habilitation at the TUD. 1977–2001 he was Professor in Chemistry at the Johannes-Gutenberg University, Mainz, Germany, and since 2001 head of a research group in bioseparations at Merck KGaA, Darmstadt. His research includes the design and synthesis of porous materials as adsorbents and catalysts, surface functionalization and characterization, development of liquid-phase separation methods, and multidimensional LC in proteomics.
|
Pascal Valax, Ph.D.Director of the Microbial Unit at Merck BioDevelopment Pascal VALAX is currently the Director of the Microbial Unit at Merck BioDevelopment (Merck Serono, Martillac, France). His main responsibilities include the development and validation of drug substance manufacturing processes for recombinant therapeutic proteins expressed in microbial systems, as well as the production of GMP material for clinical trials. Until end 2011, he held several positions including Manager of the Downstream Process Development group at Merck-Serono (Vevey, Switzerland), Purification Development Group Leader at Curagen Corporation (New Haven, CT, USA) and Associate Director in the Process Development group at Covance Biotechnology Services (Carry, NC, USA), totaling over 15 years of experience in the development and validation of purification processes for recombinant proteins. He holds a Ph.D. in Chemical Engineering from the University of Texas at Austin.
|
David W. Kahn, Ph.D.
Prof. Dr. Dirk LütkemeyerParticipate Today!
Loading ...